Tomofumi Takaya

Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study

Jonathan P. Piccini, Valeria Caso, Stuart J. Connolly et al. · The Lancet · 2022 · 296 citations · Full text

Thrombosis, Dose-finding Phase 2, Cardiovascular Disease +10

A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial Infarction

Sunil V. Rao, Bodo Kirsch, Deepak L. Bhatt et al. · Circulation · 2022 · 142 citations · Full text

Angiotensin II type 1 receptor blocker telmisartan suppresses superoxide production and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice

Tomofumi Takaya, Seinosuke Kawashima, Masakazu Shinohara et al. · Atherosclerosis · 2005 · 109 citations

Inflammation, Vascular Disease, Oxysterol +11

A Specific Role for eNOS-Derived Reactive Oxygen Species in Atherosclerosis Progression

Tomofumi Takaya, Ken‐ichi Hirata, Tomoya Yamashita et al. · Arteriosclerosis Thrombosis and Vascular Biology · 2007 · 95 citations · Full text

Effect of Daily Glucose Fluctuation on Coronary Plaque Vulnerability in Patients Pre-Treated With Lipid-Lowering Therapy

Masaru Kuroda, Toshiro Shinke, Kazuhiko Sakaguchi et al. · JACC: Cardiovascular Interventions · 2015 · 83 citations

Metabolic Syndrome, Cardiovascular Disease, Health Policy +9